Introduction
============

As a common complication of late-stage carcinomatosis, malignant ascites (MA) mainly results from metastasis, recurrence, or progression of intra- or extraperitoneal cancer, such as gastric, ovarian, and osteosarcoma.[@b1-ott-9-403] MA patients normally have an unfavorable survival and a compromised quality of life (QoL) due to complicating abdominal distension or pain, dyspnea, malnutrition, and sepsis.[@b2-ott-9-403] Surgical resection is thought to be unsuitable for these patients, while conventional palliative treatment modalities, such as conservative medical treatment, abdominocentesis, and systemic chemotherapy, show a minimal effect on the improvement of MA patients' survival and QoL.[@b3-ott-9-403]

Continuous hyperthermic intraperitoneal perfusion chemotherapy (CHIPC) is advantageous over hyperthermic intraperitoneal chemotherapy, which is also a newly emerging palliative treatment modality incorporating hyperthermia therapy and local chemotherapy for peritoneal carcinomatosis.[@b4-ott-9-403] CHIPC is normally performed using laparotomy or laparoscopy, at the risk of surgical morbidities, although the latter technique is believed to be less invasive.[@b5-ott-9-403],[@b6-ott-9-403] The previous study also indicates that there are less effects of CHIPC on the overall survival.[@b5-ott-9-403],[@b6-ott-9-403] In this study, we used ultrasound-guided abdominocentesis for catheter placement in CHIPC. The primary objective of the present work was to evaluate efficacy and safety of CHIPC with respect to body temperature change, ascites resolution, Karnofsky performance status (KPS), and serum tumor biomarkers.

Patients and methods
====================

Patients
--------

The study protocol was approved by the Institutional Review Board at the Cancer Hospital of Guangzhou Medical University in accordance with the latest version of the *Declaration of Helsinki*. Between July 2011 and June 2013, 36 MA patients were prospectively and consecutively screened for eligibility for elective CHIPC. The inclusion criteria were as follows: aged 18--75 years; diagnosed with MA confirmed on a combination of medical imaging examination, endoscopy, ascites cytology, and serum oncology; with an unresectable primary disease; with an ascites volume between 2,000 mL and 6,000 mL (the optimal range for the inclusive volume according to the preexperiments, data not shown); with a normal serum dihydropyrimidine dehydrogenase; and with a compensated cardiopulmonary or hepatorenal function reserve. The exclusion criteria were as follows: having received radical or palliative abdominal resection with 1-month time; with serious wasting or morbid obesity; with complicating serious cardiopulmonary or hepatorenal insufficiency or coagulopathy; expected to survive \<4 weeks; or rejecting to participate in this study. All the above excluded criteria, such as wasting, morbid obesity, and serious comorbidity, were defined according to the diagnosis criteria of the Zhujiang Hospital, Southern Medical University, Zhujiang, People's Republic of China. For the predicted survival definition, we have used a predictive model in the preliminary study (data not shown).

Before participating in this study, all the patients gave their informed consent and approved this study in writing.

Methods
-------

All CHIPC procedures were performed by an assigned oncologic team led by the corresponding author, including resident oncologists, anesthesiologists, radiologists, clinical pathologists, oncological nurses, and research technicians. The patient was placed supine or semisupine, and conventional abdominal ultrasound scan was performed to locate the puncture sites in the left/right, upper/lower quadrants. Under general anesthesia with endotracheal intubation or epidural anesthesia, the abdominal skin was prepared, disinfected, and draped as routine before abdominocentesis, with the inflow catheters placed in the left and right upper quadrants and the outflow catheters in bilateral lower quadrants, respectively. The perfusion catheters were connected to a BR-TRG-I CHIPC system (Guangzhou Bright Medical Technology Co., Ltd, Guangzhou, People's Republic of China) with a ±5% flow rate precision, ±0.15°C temperature control, and automatic cooling function, approved by China Food and Drug Administration (license number 2009-3260924), and also equipped with temperature sensors for continuous monitoring of perfusate and body temperature over CHIPC.[@b7-ott-9-403] The perfusion solution consisted of 3,500--6,000 mL normal saline and 1,500 mg 5-fluorouracil, and the perfusion was maintained at a constant temperature of 43°C±0.2°C and at a flow rate of 400--600 mL/min for 90 minutes. The first cycle of CHIPC was done in the operating room, while the next two cycles were given in the ward using the same protocol, after the patient was intramuscularly premedicated with 25 mg promethazine and 75 mg pethidine, at an interval of 1 week. In the last cycle of CHIPC, 80 mg carboplatin was added into the perfusate for malignant gastrointestinal stromal tumors (GISTs) and ovarian cancers, while 10 mg mitomycin was added for liver, gastric, colon, and pancreatic cancers. Intravenous systemic chemotherapy was initiated 6 weeks after CHIPC as indicated. Main outcome measures were ascites resolution, KPS, and serum carcinoembryonic antigen (CEA) as well as carbohydrate antigens 12-5 (CA12-5) and 19-9 (CA19-9) 2 weeks after the last cycle of CHIPC. Resolution of ascites was defined as follows: complete response, ≥75% resolution of ascites maintaining \>4 weeks; partial response, 50%−75% resolution of ascites maintaining \>4 weeks; and no response, \<50% resolution or recurrence of ascites.[@b8-ott-9-403]

Statistical analysis
--------------------

The statistical software package SPSS 17.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. All continuous data were expressed as mean ± standard deviation, and the means were compared using the paired Student's *t*-test. A two-tailed *P*\<0.05 was considered to be statistically significant.

Results and discussion
======================

Overall, 36 patients, including 16 men and 20 women, at a median age of 49 years (35--73 years) and with a KPS score of 40−70 were studied. The disease history was 7 days to 5 months (mean, 1.1 months) to the time of diagnosis. The underlying primary disease was gastric cancer (n=12), ovarian cancer (n=12), colon cancer (n=8), pancreatic cancer (n=2), postoperative hepatocellular carcinoma (n=1), and postoperative malignant GIST (n=1).

All the patients underwent uneventful CHIPC as scheduled and vital signs remained stable over CHIPC ([Table 1](#t1-ott-9-403){ref-type="table"}; all *P*\>0.05). Ascites completely resolved in 26 (72.2%) patients, partially resolved in eight (22.2%) patients, and with no significant response in two (5.6%) patients. Mean KPS score increased from pretreatment 61±9 to posttreatment 76±9 (*P*\<0.001), and serum CEA and CA 12-5 and 19-9 significantly decreased (all *P*\<0.01; [Table 2](#t2-ott-9-403){ref-type="table"}).

During the follow-up at the outpatient clinic visits, the patients complained of no clinically significant adverse events, except for mild abdominal distension or discomfort and transient fever. Follow-up liver and renal function tests showed no clinically significant abnormalities. Grades I and II bone marrow suppression occurred in four (11.1%) patients, and mild gastrointestinal reaction in six (16.7%) patients, all of which resolved after symptomatic treatment. No peritoneal sepsis, bowel adhesion, intestinal obstruction, or puncture site metastasis occurred. All patients were followed-up as scheduled for 2--12 months (median, 7 months), and the survival curve is depicted in [Figure 1](#f1-ott-9-403){ref-type="fig"}.

MA patients usually exhibit a dismal survival ranging from weeks to months, at 1-year overall survival below 10%.[@b1-ott-9-403] Effective elimination or control of ascites may be beneficial for MA patients with respect to improvement of overall survival and QoL.[@b1-ott-9-403] CHIPC is a palliative treatment modality that has been well documented for peritoneal carcinomatosis manifesting as refractor or recurrent ascites. Tumor cells are normally sensitive to hyperthermia, which significantly increases cell membrane permeability to drugs. Large-volume hyperthermic perfusate allows adequate exposure of free tumor cells and tumor micrometastases to chemotherapeutic agents in a constant and continuous manner. Moreover, CHIPC is associated with relatively less toxicities as it results from the entry of a significantly lower dose chemotherapeutic agent into the blood stream as compared to systemic chemotherapy. Thus, CHIPC is reported to be advantageous over systemic or intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis including MA.[@b4-ott-9-403]--[@b8-ott-9-403]

In previous reports,[@b4-ott-9-403]--[@b12-ott-9-403] CHIPC was usually performed using laparotomy or laparoscopy, which allowed a direct visualization of intraperitoneal disease and placement of perfusion catheters. However, laparotomy- or laparoscopy-assisted CHIPC may result in some surgical morbidities and require delicate postoperative care. In contrast, ultrasound-guided percutaneous access is a minimally invasive interventional imaging modality for diagnosis, follow-up, and treatment of MA, with a good accuracy, reproducibility, and cost-effectiveness.[@b13-ott-9-403],[@b14-ott-9-403] Our results showed that ultrasound-guided CHIPC had a good efficacy and safety profile. CHIPC effectively resolved ascites and improved patients' general well-being in association with the control of systemic disease within a short time as shown by follow-up examination.

Treatment-emergent hyperthermia is a major safety concern over CHIPC,[@b15-ott-9-403] aside from puncture- and chemotherapy-associated morbidities, as the parietal and visceral peritonea can efficiently absorb the heat. Increased body temperature may have an adverse impact on the patient's circulatory, respiratory, neurologic, and metabolic functions. Our results demonstrated that peritoneal perfusion at a constant temperature (43°C±0.2°C) and flow rate (400−600 mL/min) resulted in a clinically insignificant increase in body temperature without significantly altering the patient's physiologic condition.

There were some limitations in this study. First, the sample size was relatively small; however, to the best of our knowledge, the present work was the largest study evaluating efficacy and safety of ultrasound-guided CHIPC for the treatment of MA. Second, the effect of peritoneal hyperthermia on the patient's general well-being and tolerability was not fully studied, although the increase of body temperature was \<1°C in extent and transient in duration. Finally, the benefit of ultrasound-guided CHIPC remained undetermined in this study with respect to overall survival, while the long-term follow-up study is ongoing in our institute.

Conclusion
==========

In conclusion, CHIPC is an effective and safe palliative treatment modality for MA with respect to resolution of ascites, improvement of patient's general well-being, and control of intraperitoneal disease. Hyperthermia is a major CHIPC-emergent adverse event, while it has insignificant effects on the patient's cardiopulmonary status due to its mild severity and transient duration. The benefit of CHIPC for overall survival of MA patients, who normally have a dismal prognosis, remains yet to be investigated in further long-term follow-up studies.
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###### 

Changes in vital signs (mean ± SD) over CHIPC (n=36)

                       0 minutes   30 minutes                                           60 minutes                                                                                      90 minutes
  -------------------- ----------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  BT, °C                                                                                                                                                                                
   Axilla              36.3±0.3    37.0±0.3[\*](#tfn1-ott-9-403){ref-type="table-fn"}   37.3±0.5[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"}   37.2±0.4[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"},[\$](#tfn3-ott-9-403){ref-type="table-fn"}
   Rectum              36.7±0.6    37.4±0.4[\*](#tfn1-ott-9-403){ref-type="table-fn"}   37.5±0.3[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"}   37.4±0.3[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"},[\$](#tfn3-ott-9-403){ref-type="table-fn"}
   Tympanic membrane   36.0±0.2    37.6±0.2[\*](#tfn1-ott-9-403){ref-type="table-fn"}   36.7±0.2[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"}   36.6±0.2[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"},[\$](#tfn3-ott-9-403){ref-type="table-fn"}
   HR, bpm             73±8        76±6[\*](#tfn1-ott-9-403){ref-type="table-fn"}       79±8[\*](#tfn1-ott-9-403){ref-type="table-fn"}                                                  79±9[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"},[\$](#tfn3-ott-9-403){ref-type="table-fn"}
  BP, mmHg                                                                                                                                                                              
   Systolic            122±8       119±9[\*](#tfn1-ott-9-403){ref-type="table-fn"}      115±7[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"}      117±8[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"},[\$](#tfn3-ott-9-403){ref-type="table-fn"}
   Diastolic           80±5        77±6[\*](#tfn1-ott-9-403){ref-type="table-fn"}       76±4[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"}       76±6[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"},[\$](#tfn3-ott-9-403){ref-type="table-fn"}
   RR, brpm            16±2        18±2[\*](#tfn1-ott-9-403){ref-type="table-fn"}       17±2[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"}       18±2[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"},[\$](#tfn3-ott-9-403){ref-type="table-fn"}
   SpO~2~, %           99±1        98±2[\*](#tfn1-ott-9-403){ref-type="table-fn"}       98±1[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"}       98±2[\*](#tfn1-ott-9-403){ref-type="table-fn"},[\#](#tfn2-ott-9-403){ref-type="table-fn"},[\$](#tfn3-ott-9-403){ref-type="table-fn"}

**Notes:**

*P*\>0.05 represents the significant difference at 30 minutes, 60 minutes, or 90 minutes compared to that at 0 minutes.

*P*\>0.05 represents the significant difference at 60 minutes or 90 minutes compared to that at 30 minutes.

*P*\>0.05 represents the significant difference at 90 minutes compared to that at 60 minutes.

**Abbreviations:** CHIPC, continuous hyperthermic intraperitoneal perfusion chemotherapy; BT, body temperature; HR, heart rate; bpm, beats per minute; BP, blood pressure; RR, respiratory rate; brpm, breaths per minute; SpO~2~, pulse oxygen saturation.

###### 

Pre- to post-CHIPC changes (mean ± SD) in KPS score and serum tumor biomarkers (n=36)

                                 Pre-CHIPC   Post-CHIPC
  ------------------------------ ----------- -----------------------------------------------------
  KPS, point                     61±9        76±9[\*](#tfn5-ott-9-403){ref-type="table-fn"}
  Serum tumor biomarkers, U/mL               
   CEA                           59.0±9.1    47.1±8.0[\*](#tfn5-ott-9-403){ref-type="table-fn"}
   CA12-5                        890±176     712±150[\*\*](#tfn6-ott-9-403){ref-type="table-fn"}
   CA19-9                        398±65      309±54[\*](#tfn5-ott-9-403){ref-type="table-fn"}

**Notes:**

*P*\<0.001 represents the significant differences of KPS, CEA, or CA19-9 level in post-CHIPC group compared to pre-HCIPC group.

*P*\<0.05 represents the significant differences of CA12-5 level in post-CHIPC group compared to pre-CHIPC group.

**Abbreviations:** CHIPC, continuous hyperthermic intraperitoneal perfusion chemotherapy; KPS, Karnofsky performance status; CEA, carcinoembryonic antigen; CA, carbohydrate antigen.
